Patents by Inventor Christopher Stephen TOWLER

Christopher Stephen TOWLER has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20260167608
    Abstract: The present disclosure provides polymorphs and formulations of 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile (compound I). The present disclosure further provides methods for treating ocular surface pain by administering 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile (compound I). The present invention also provides methods for treating dry eye disease and ocular hyperemia by administering 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile.
    Type: Application
    Filed: October 17, 2025
    Publication date: June 18, 2026
    Inventors: Joseph Paul BULLOCK, Chinmay MAHESHWARI, Quintus MEDLEY, Muneto MOGI, Michela MONTECCHI-PALMER, Gregory MORANDI, Michael MUTZ, Kalliopi STASI, Christopher Stephen TOWLER
  • Patent number: 12600702
    Abstract: The present disclosure provides polymorphs and formulations of 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile (compound I). The present disclosure further provides methods for treating ocular surface pain by administering 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile (compound I). The present invention also provides methods for treating dry eye disease and ocular hyperemia by administering 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile.
    Type: Grant
    Filed: February 13, 2020
    Date of Patent: April 14, 2026
    Assignee: Bausch + Lomb Ireland Limited
    Inventors: Joseph Paul Bullock, Chinmay Maheshwari, Quintus Medley, Muneto Mogi, Michela Montecchi-Palmer, Gregory Morandi, Michael Mutz, Kalliopi Stasi, Christopher Stephen Towler
  • Publication number: 20240238305
    Abstract: Formulations of 3-((3-(4-(2-(isobutylsulfonyl)phenoxy)-3-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-yl)methyl)-5,5-dimethyl-1-(2-morpholinoethyl)imidazolidine-2,4-dione and pharmaceutically acceptable salts thereof, processes for their production, and uses thereof, including in the treatment of ocular diseases and disorders such as dry eye disease and Meibomian gland dysfunction (MGD).
    Type: Application
    Filed: May 18, 2022
    Publication date: July 18, 2024
    Inventors: Yi FAN, Declan HARDY, Zhihong HUANG, Jay Parthiban LAKSHMAN, Jon Christopher LOREN, Valentina MOLTENI, Sunil Kumar Mandala RAYABANDLA, Nuria Jimenez RIDRUEJO, Duncan SHAW, Jeffrey SMITH, Christopher Stephen TOWLER
  • Publication number: 20220162170
    Abstract: The present disclosure provides polymorphs and formulations of 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile (compound I). The present disclosure further provides methods for treating ocular surface pain by administering 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile (compound I). The present invention also provides methods for treating dry eye disease and ocular hyperemia by administering 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile.
    Type: Application
    Filed: February 13, 2020
    Publication date: May 26, 2022
    Inventors: Joseph Paul BULLOCK, Chinmay MAHESHWARI, Quintus MEDLEY, Muneto MOGI, Michela MONTECCHI-PALMER, Gregory MORANDI, Michael MUTZ, Kalliopi STASI, Christopher Stephen TOWLER